Macular dystrophies represent a heterogeneous group of disorders spanning a broad spectrum of clinical, histopathological, and laboratory findings. Despite this variability, funduscopic changes involving the macula and retinal pigment epithelium (RPE) and clinically significant loss of central or functional vision are characteristic of these disorders. As a group of diseases with a strong genetic component, many macular dystrophies are excellent candidates for study using molecular biological techniques such as genetic linkage analysis, positional cloning, and the candidate gene approach. Such molecular investigations have been successful, and genes for several inherited maculopathies including Stargardt's macular dystrophy,'" North Carolina macular dystrophy, 45 Best's vitelliform macular dystrophy,6 and Sorsby's macular dystrophy78 have been mapped to specific chromosomal loci. In addition to elucidating the aetiology and pathogenesis of these rare heritable disorders, it is hoped that the identification of individual genes and molecular pathways involved in inherited macular dystrophies will give greater insight into the more complex aetiology of age-related macular degeneration (ARMD).
ARMD is the most common cause of blindness among the elderly in many Western countries including the UK and the USA.9-"' By 1996, it is estimated that over two million people in the USA alone will have ARMD, and more than 100 000 will probably be blind from the disease.'2 Despite its prevalence, the aetiology and molecular pathogenesis of ARMD are poorly understood." This finding makes a rational approach to treatment difficult, and therapeutic options for ARMD limited. Direct application of molecular genetic techniques to ARMD is hindered by two major factors. Firstly, the late onset of ARMD makes genetic linkage experiments difficult because the parents of affected individuals are often deceased and the children of affected members are often too young to express the ARMD phenotype. Secondly, although genetic studies involving monozygotic twins suggest a major genetic component,'"" ARMD in most patients is probably multifactorial including both genetic and environmental factors. For example, a high dietary intake of carotenoids has been associated with a lower risk of ARMD,'8 whereas a high risk of ARMD has been associated with atherosclerosis in a study population in Rotterdam.'9 Owing to these difficulties monogenic maculopathies sharing important clinical and histopathological findings with ARMD have been studied. Here, we review recent developments in this field and discuss the results with regard to the application of these techniques to the study of ARMD. were identified using the single stranded conformational polymorphism (SSCP) method, and sequencing of the exon led to the identification oftwo missense mutations. In one mutation, a cysteine residue was substituted for a serine, and in another, a cysteine was substituted for a tyrosine. Though the detection of mutations in TIMP-3 in patients is not proof that these mutations are the cause of the SFD phenotype, the failure to detect these changes in normal individuals strongly suggests these mutations as the principal molecular defect in this disease.
Classification of inherited macular dystrophies
Remodelling ofthe collagen, laminin, fibronectin, proteoglycans, and glycosaminoglycans in the extracellular matrix is an active process essential to normal development. This process is usually governed by a balance between proteinases, including serine, cysteine, and matrix metalloproteinases (MMPs), and the inhibitors of these proteinases including the family of tissue inhibitors of metalloproteinases (TIMPs). It If specific mutations are found in macular dystrophies that also are associated with a subset of ARMD, the mechanism of pathogenesis may then be studied using cell culture or transgenic animals. For example, mice could be genetically engineered to carry a mutant gene causing ARMD. Such systems are more practical to-study than the human population. One must be aware, however, that not all of the features of the human macula are represented in lower vertebrates, such as mice. Nevertheless, if new therapeutic treatments were developed with these models, they could be applied to patients with ARMD or other hereditary degenerations.
Much progress has been made in the genetics and molecular biology of macular dystrophies. The mapping of the genes involved in macular dystrophies may offer significant insight into the mechanism of the pathogenesis of macular degeneration and therefore insight into ARMD. It is hoped that such genetic and molecular studies will contribute increasingly to the clinical diagnosis, management, and treatment of patients with macular degeneration in the years to come.
